Lifestyle Changes Deserve a 3-Month Trial

Efficacy of the daily pill met the standard now established by the once-weekly injection of 15% loss of baseline bodyweight in adults with overweight or obesity, says Novo Nordisk.

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Results of a Mendelian randomization study showed earlier first birth, higher number of live births, and earlier menarche are all associated with increased CVD.

In episode 3 of Primary Viewpoints, Brigham and Women's hypertension expert Naomi Deirdre Fisher, MD, discusses the challenges of hypertension management in primary care.

Young women who survived a myocardial infarction may have nearly double the risk of rehospitalization in the year after discharge compared to men, according to a new study.

Researchers found that reliable improvement of depressive symptoms after psychological therapy was associated with a 12% decrease in CVD risk at any given time.